🚀 go-pugleaf

FOR IMMEDIATE NEWS RELEASE:
NOVA GEN INC. (JULY 98)
JULY 27, 1998


                      Contact: Sam Rao
                          Tel. (510) 795-8581     Fax. (510) 795-7571
			  e-mail: nova_gen@hotmail.com


San Francisco, CA.  

Nova Gen, Inc.- an emerging Bio Tech company -founded 1994- specializing 
in  unique Biomaterials and  Medical Devices - announces  the award of 
an U.S. Patent allowance (March 1998) for the cutting edge technology of  
preparation of  Ultrapure Collagen as a Novel Biomaterial.

Collagen has become an important tool for hastening the healing process 
of injured tissues. Nova Gen  has developed proprietary methods 
(U.S.Patent allowed March 1998) to manufacture highly purified collagen, 
and to make other surface modifications to enhance bioactivity of the 
protein.  
The Twice Treatment Process (TTP) and other unique purification steps of 
the patented technology results in a less immunogenic and better 
biocompatible collagen than that are currently available in the 
commercial market (proven pre-clinical studies).  

This energized pure (99%) collagen, "CollagenPRO", can be used for 
different biomedical applications.
1. Superior Wound Healing products (HealiColl, HemoColl) used as 
resorbable dressing materials for external wounds, burns, bed sores and 
diabetic ulcers etc.
2. Surgical Products  and Implants like tissue  glues,  fillers and 
resorbable sutures including Gum    
      infection management product (PerioColl)
3. Skin care products (NeoSkin  and SkinFader) and Purified  raw 
collagen for cosmetic use. 
4. Research products including  collagen coated surgical products such 
as shunts, catheters and   implants, Biotech products like cell-culture 
plates (CollagenPRO  COAT); and 
5.   Gene therapy  products (Collatrix) .

 "Nova Gen's  proprietary collagen  modification technology  will enable 
the company to become a leader in this field.  Our  technology hopes to 
bring a revolution in collagen research. It will provide a better 
surface chemistry to the collagen,  thus allowing it  to attach with 
chemicals and drugs in a more natural and effective manner, unlike other 
collagen preparations available in the market today, " added Dr. Guna,  
the President and CEO of  Nova Gen Inc., and a well known scientist in 
the field.  One of the major US distributors for Research Products has 
tested, and is willing to include Nova Gen's CollagenPR0 COAT product in 
their 1999 catalog.

The market for Gene delivery for  therapeutic applications is estimated 
to reach $45 Billion by the year 2010 (Business Week, Jan. 1997).  The 
current market size for collagen based skin care products and wound 
healing products is estimated by Nova Gen as $0.5 billion and $1.26 
billion respectively and the market size for surgical products and 
research products is approximately $0.25 billion and $0.58 billion 
respectively (Burril and Company -'97,  Theta Corp. Nov. '96).  Inspite 
of all these figures, there seems to be a definite void between  the 
supply and demand for quality Collagen (Frost & Sullivan, 1995) .  Nova 
Gen is confident of filling in the shortage of supply.  

The corporate head quarters of Nova Gen, Inc. is located in Newark, CA  
(San Francisco Bay area), and the laboratory is in Fremont, CA with an 
adequate R&D facility.  "Based on very encouraging pre-clinical studies 
at the Stanford University and the VA Research center in Palo Alto, CA, 
our company is poised to make significant advancements in the field of 
biomaterials," said Dr. Guna, CEO at Nova Gen, Inc.


DISCLAIMER:  Statements contained in this Press Release including those 
pertaining to scientific, pre-clinical research and  market projections 
etc., are subject to a number of uncertainties.  The announcing company 
or persons involved are not liable in any manner. EOE